Key Points
- Insider sale: Replimune Group insider Christopher Sarchi sold 12,000 shares on June 1 at an average price of $9.24, for proceeds of about $110,880. The sale reduced his position by 6.22% and was made under a pre-arranged Rule 10b5-1 plan.
- Recent trading history: Sarchi also sold 6,500 shares in April at an average price of $8.01, bringing his recent total selling activity to multiple transactions this year.
- Analyst sentiment remains cautious: Wall Street analysts currently have a consensus rating of Reduce on REPL, with an average price target of $4.88. Several firms have recently cut ratings or lowered targets, even as the stock traded around $9.98.
Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) insider Christopher Sarchi sold 12,000 shares of the business's stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $9.24, for a total value of $110,880.00. Following the completion of the transaction, the insider owned 180,962 shares in the company, valued at $1,672,088.88. This trade represents a 6.22% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Christopher Sarchi also recently made the following trade(s):
- On Thursday, April 2nd, Christopher Sarchi sold 6,500 shares of Replimune Group stock. The shares were sold at an average price of $8.01, for a total value of $52,065.00.
Replimune Group Stock Performance
Shares of REPL stock opened at $9.98 on Thursday. The stock has a market capitalization of $824.05 million, a PE ratio of -2.90 and a beta of 0.91. Replimune Group, Inc. has a 52-week low of $1.50 and a 52-week high of $13.24. The stock's 50-day moving average price is $5.02 and its 200 day moving average price is $7.26. The company has a quick ratio of 5.60, a current ratio of 5.60 and a debt-to-equity ratio of 0.33.
Institutional Investors Weigh In On Replimune Group
Institutional investors have recently modified their holdings of the company. International Assets Investment Management LLC purchased a new stake in shares of Replimune Group during the 4th quarter worth approximately $29,000. Russell Investments Group Ltd. boosted its stake in shares of Replimune Group by 3,638.9% during the 3rd quarter. Russell Investments Group Ltd. now owns 7,777 shares of the company's stock worth $33,000 after acquiring an additional 7,569 shares in the last quarter. CWM LLC boosted its stake in shares of Replimune Group by 248.6% during the 4th quarter. CWM LLC now owns 4,047 shares of the company's stock worth $39,000 after acquiring an additional 2,886 shares in the last quarter. Essential Partners LLC lifted its stake in Replimune Group by 562,400.0% in the 1st quarter. Essential Partners LLC now owns 5,625 shares of the company's stock valued at $43,000 after buying an additional 5,624 shares in the last quarter. Finally, BNP Paribas Financial Markets lifted its stake in Replimune Group by 99.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 13,762 shares of the company's stock valued at $58,000 after buying an additional 6,873 shares in the last quarter. Hedge funds and other institutional investors own 92.53% of the company's stock.
Wall Street Analyst Weigh In
Several equities analysts have issued reports on REPL shares. Piper Sandler cut Replimune Group from an "overweight" rating to a "neutral" rating and set a $4.00 target price on the stock. in a research report on Friday, April 10th. Wedbush boosted their target price on Replimune Group from $2.00 to $6.00 and gave the stock a "neutral" rating in a research report on Monday. Cantor Fitzgerald cut Replimune Group from an "overweight" rating to a "hold" rating in a research report on Monday, April 13th. HC Wainwright reiterated a "sell" rating on shares of Replimune Group in a research report on Monday, April 13th. Finally, Jefferies Financial Group reiterated a "hold" rating and set a $2.00 target price (down from $13.00) on shares of Replimune Group in a research report on Monday, April 13th. Seven investment analysts have rated the stock with a Hold rating and three have assigned a Sell rating to the company's stock. According to data from MarketBeat, Replimune Group has an average rating of "Reduce" and a consensus price target of $4.88.
View Our Latest Stock Report on REPL
Replimune Group Company Profile
(
Get Free Report)
Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company's proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.
Replimune's lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
